LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT. (2024). Mediterranean Journal of Hematology and Infectious Diseases, 16(1), e2024039. https://doi.org/10.4084/MJHID.2024.039